MAPT and Alzheimer disease: We have outlined multiple mechanisms through which these drugs function to therapize and improve the clinical course of AD both in vitro and in vivo; however, the central fact across each mechanism remains the same and that is the antidiabetic’s ability to target and ameliorate the key pathologies of AD: amyloid beta and tau hyperphosphorylation.